A Phase 1 clinical trial involving insulin glargine has reached completed status as of October 23, 2026. The study, registered as NCT06627478, was titled "Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS Glargine (G), United States (US)-Lantus, and European Union (EU)-Lantus." The trial aimed to compare pharmacokinetic and pharmacodynamic profiles between NKF-INS glargine and both the US and EU versions of Lantus. This was a Phase 1 study. The trial status is listed as completed. No results or outcome data were provided in this update. The event record does not include efficacy, safety, or comparative findings beyond the confirmation that the study has concluded. Insulin glargine remains an approved compound. Readers interested in the background of this compound and its regulatory history can consult the compound overview for additional context.
Insulin Glargine Trial NCT06627478 Completes Phase 1
See the full insulin glargine overview
Source: https://clinicaltrials.gov/study/NCT06627478